SPOTlight on GLOW

Sarah Derks; Hanneke W M van Laarhoven

doi:10.1016/j.xcrm.2023.101233

SPOTlight on GLOW

Cell Rep Med. 2023 Oct 17;4(10):101233. doi: 10.1016/j.xcrm.2023.101233.

Authors

Sarah Derks¹, Hanneke W M van Laarhoven²

Affiliations

¹ Amsterdam UMC location Free University, Medical Oncology, De Boelelaan 1118, Amsterdam, the Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands. Electronic address: s.derks@amsterdamumc.nl.
² Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands; Amsterdam UMC location University of Amsterdam, Medical Oncology, Meibergdreef 9, Amsterdam, the Netherlands.

Abstract

The GLOW randomized double-blind phase 3 trial¹ shows that Claudin-18.2 targeting antibody zolbetuximab combined with capecitabine and oxaliplatin improves outcome compared to placebo and chemotherapy as first-line treatment in Claudin-18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.

Publication types

Clinical Trial, Phase III
Randomized Controlled Trial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Capecitabine / therapeutic use
Claudins / therapeutic use
Esophageal Neoplasms* / drug therapy
Humans
Receptor, ErbB-2
Stomach Neoplasms* / drug therapy
Stomach Neoplasms* / pathology

Substances

Capecitabine
Claudins
Receptor, ErbB-2